Saudi FDA allows more time to address deficiencies in drug submissions
This article was originally published in SRA
The Saudi Food and Drug Authority has issued a revised guideline that provides pharmaceutical companies with more time to respond to deficiencies in their submissions concerning new marketing authorisations, renewals and variations to existing products1,2.
You may also be interested in...
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.